BERKELEY, Calif. -- (BUSINESS WIRE) -- Aduro BioTech, Inc., a clinical stage biotechnology company, today announced that the company’s chairman and chief executive officer, Stephen T. Isaacs, will present a company overview at the following upcoming conferences:
To access the live webcast and subsequent archived recording of the BIO CEO and Investor Conference presentation, please visit the company’s website at www.adurobiotech.com
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a clinical-stage biotechnology company focused on immunotherapy for cancer. Aduro has ongoing clinical development programs in pancreatic cancer, mesothelioma and glioblastoma. The company is also developing clinical candidates that utilize small molecules that activate STING (stimulator of interferon genes), a central mediator of the innate immune response. The company’s pipeline also includes programs in non-small-cell lung cancer, ovarian cancer and prostate cancer. For more information, please visit www.adurobiotech.com.